cocaine hydrochloride nasal
NUMBRINO (cocaine hydrochloride nasal) is type. First approved in 2020.
Drug data last refreshed 1h ago · AI intelligence enriched 1h ago
NUMBRINO is a nasal solution containing cocaine hydrochloride approved in 2020 for topical nasal use. It functions as a local anesthetic and vasoconstrictor by blocking voltage-gated sodium channels in nerve fibers, preventing action potential generation. The product is indicated for nasal procedures requiring topical anesthesia and vasoconstriction.
Product is in peak lifecycle with established market presence, suggesting stable commercial operations and moderate-sized field and marketing teams.
type. Cocaine hydrochloride prevents conduction in nerve fibers by reversibly blocking voltage-gated sodium channels and preventing the transient rise in sodium conductance necessary for generation of an action potential.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NUMBRINO offers stability in a specialized procedural niche with limited competitive pressure and strong patent protection through 2037. Career growth may be constrained by the focused indication and lack of active pipeline expansion, but the product's secure market position provides long-term employment stability.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo